Welcome to our dedicated page for Edesa Biotech news (Ticker: EDSA), a resource for investors and traders seeking the latest updates and insights on Edesa Biotech stock.
Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company whose news flow centers on the development of host-directed therapeutics for immuno-inflammatory diseases. Company announcements frequently highlight progress in its two main therapeutic areas, Medical Dermatology and Respiratory, giving investors and observers insight into the status of key clinical programs and funding arrangements.
On this page, readers can follow updates on Edesa’s dermatology pipeline, including news about EB06, an anti-CXCL10 monoclonal antibody candidate being developed as a therapy for vitiligo, and EB01 (1.0% daniluromer cream), a Phase 3-ready asset for moderate-to-severe chronic Allergic Contact Dermatitis. Disclosures often cover manufacturing milestones, regulatory interactions and plans for Phase 2 and Phase 3 clinical studies in these indications.
The news feed also captures developments in Edesa’s respiratory portfolio. This includes clinical data and regulatory context for paridiprubart (EB05), a monoclonal antibody being developed for Acute Respiratory Distress Syndrome (ARDS), as well as information on the U.S. government-funded “Just Breathe” platform study and Canadian government funding from the Strategic Innovation Fund. Announcements may detail Phase 3 study outcomes, safety findings, and the company’s exploration of additional uses for paridiprubart in chronic respiratory diseases and pulmonary fibrosis via EB07.
In addition to clinical and scientific news, Edesa’s releases include financial results, equity financings, at-the-market offering updates, and executive or board changes. Visitors can use this page to monitor how Edesa reports on its operating expenses, government contribution agreements, capital raises and conference participation. For those tracking EDSA, the news section provides a centralized view of the company’s disclosed milestones, strategic priorities and regulatory progress over time.
Edesa Biotech (Nasdaq:EDSA) reported fiscal year 2025 results for the year ended September 30, 2025, highlighting clinical and financial updates. The company said a Phase 3 study of paridiprubart (EB05) met primary and secondary endpoints with statistical significance and that manufacturing activities began for a Phase 2 study of EB06 (anti-CXCL10) in vitiligo with recruitment anticipated by mid‑2026, subject to manufacturing and approvals. Financials showed total operating expenses $7.9M (up $0.9M), R&D $3.7M (up $0.8M), net loss $7.2M or $1.27 per share, cash and equivalents $10.8M, and working capital $10.4M. The company received $3.4M net proceeds from an at‑the‑market offering after year‑end and extended Canadian government funding to support programs.
Edesa Biotech (Nasdaq: EDSA) announced management and business development participation at two upcoming industry conferences in Europe: BIO-Europe in Vienna, Austria on November 3-5, 2025, and LSX Investival Showcase Europe in London, UK on November 17, 2025 (presentation at 3:45 pm GMT). To schedule meetings during these events, investors should contact conference organizers or email investors@edesabiotech.com.
Edesa Biotech (Nasdaq: EDSA) reported positive Phase 3 results for paridiprubart (EB05) in Acute Respiratory Distress Syndrome (ARDS) on Oct 28, 2025. In the ITT population (n=104) paridiprubart plus standard of care reduced 28‑day mortality to 39% vs 52% for placebo (absolute improvement 13%, relative risk reduction 25%, p<0.001). At 60 days mortality was 46% vs 59% (absolute improvement 13%, relative reduction 22%, p=0.003). Paridiprubart also produced a 41% higher relative rate of clinical improvement at Day 28. Safety in a population >275 subjects was reported as generally well tolerated.
Edesa Biotech (Nasdaq:EDSA) reported its fiscal Q3 2025 results and provided updates on its drug development programs. The company is advancing manufacturing activities for EB06, an anti-CXCL10 monoclonal antibody for moderate-to-severe nonsegmental vitiligo, with FDA submission planned by end of 2025.
Financial highlights include: Q3 net loss of $1.7 million ($0.25 per share), unchanged from last year, with operating expenses stable at $1.9 million. The company maintains a strong financial position with $12.4 million in cash and $12.1 million in working capital. The company's EB05 program continues through a fully funded U.S. government "Just Breathe" study for ARDS patients.
Edesa Biotech, a clinical-stage biopharmaceutical company, has announced its upcoming participation in the 2024 Bloom Burton & Co. Healthcare Investor Conference. The event is scheduled to take place in Toronto, Ontario on May 5-6, 2025.
Key Details:
- Presentation Date: Monday, May 5, 2025
- Time: 4:00 PM Eastern Time
- Location: Toronto, Ontario
The company, which specializes in developing host-directed therapeutics for immuno-inflammatory diseases, has made its management team available for meetings during the conference. Interested parties can schedule meetings through either the conference's online portal or by directly contacting Edesa at investors@edesabiotech.com.
NeuPath Health has appointed Stephen Lemieux as President in a newly created role, effective May 1, 2025. Lemieux, who previously served as the company's CFO from 2019 to 2021, brings over 20 years of executive experience in healthcare and biopharmaceutical sectors.
As President, Lemieux will focus on implementing NeuPath's growth strategy, including:
- Accelerating inorganic and organic growth
- Optimizing operating margins
- Expanding service offerings and locations
- Pursuing strategic acquisitions
- Exploring adjacent market opportunities
The appointment follows NeuPath's successful financial and operational turnaround and newly secured credit facilities. During his previous tenure as CFO, Lemieux led NeuPath's expansion into Alberta. He most recently served as CFO at Edesa Biotech.
Edesa Biotech (NASDAQ:EDSA) has announced a leadership transition in its financial department. Peter J. Weiler will assume the role of Chief Financial Officer effective May 1, 2025, replacing Stephen Lemieux who is stepping down to pursue other opportunities.
Weiler brings significant experience from the biotech and pharmaceutical sectors, most recently serving as President of Exzell Pharma. His prior roles include VP of Business Development at Biosyent Inc. and various positions at Cipher Pharmaceuticals. He holds an MBA from Ivey School of Business, an MSc in Biology, and a BSc in Biology with a Diploma in Accounting.
Following the transition, Lemieux will continue providing financial advisory services to Edesa. CEO Par Nijhawan expressed confidence in Weiler's ability to support the company's pipeline advancement and strategic initiatives.
Edesa Biotech (NASDAQ:EDSA) reported its fiscal Q1 2025 results and provided business updates. The company is advancing EB06, an anti-CXCL10 monoclonal antibody for vitiligo treatment, with FDA data submission planned for mid-2025. A Phase 2 study for moderate-to-severe nonsegmental vitiligo patients is anticipated, with topline results expected 12-18 months after FDA clearance.
Financial highlights include unchanged total operating expenses at $1.9 million, with R&D expenses increasing to $1.0 million and G&A expenses decreasing to $0.9 million. The company reported a net loss of $1.6 million ($0.48 per share) compared to $1.7 million ($0.54 per share) in the previous year. Post-quarter, Edesa secured $15.0 million in gross proceeds through a private placement of preferred and common shares.
Edesa Biotech (NASDAQ: EDSA) has secured a $15.0 million private placement through the sale of 834 Series B-1 convertible preferred shares at $10,000 per share and 3,468,746 common shares at $1.92 per share. The placement was led by Velan Capital, with participation from new investors including Nantahala Capital, Rubric Capital Management LP, and others.
Company officers and directors invested approximately $1.1 million in the offering. The proceeds will fund the advancement of EB06, Edesa's CXCL10 monoclonal antibody, into a Phase 2 clinical study for nonsegmental vitiligo through fiscal 2026. The Series B-1 Preferred Shares are convertible to common shares at $1.92, with ownership limitations of 4.99% or 9.99%. As part of the agreement, David Liu from Velan Capital joined Edesa's Board of Directors.
FAQ
What is the current stock price of Edesa Biotech (EDSA)?
What is the market cap of Edesa Biotech (EDSA)?
